Evidence map›Paper›PMID 31767870›Full record

ArticleNature communications2019

Publisher Correction: An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence.

Chang-Han Lee, Tae Hyun Kang, Ophélie Godon, Makiko Watanabe, George Delidakis, Caitlin M Gillis, Delphine Sterlin, David Hardy, Michel Cogné, Lynn E Macdonald and 9 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Chang-Han LeeDepartment of Chemical Engineering, University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0002-7156-4423
Tae Hyun KangDepartment of Chemical Engineering, University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0002-7825-5877
Ophélie GodonUnit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERMF-75015, Paris, France.
Makiko WatanabeDepartment of Chemical Engineering, University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0002-6694-3066
George DelidakisDepartment of Chemical Engineering, University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0002-4330-9476
Caitlin M GillisUnit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERMF-75015, Paris, France.ORCID http://orcid.org/0000-0001-9892-206X
Delphine SterlinUnit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERMF-75015, Paris, France.
David HardyExperimental Neuropathology Unit, Infection and Epidemiology Department, Institut Pasteur, 25, rue du Docteur Roux, 75015, Paris, France.
Michel CognéLimoges University, Limoges, France.
Lynn E MacdonaldRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Andrew J MurphyRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.ORCID http://orcid.org/0000-0003-4152-4081
Naxin TuRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Jiwon LeeThayer School of Engineering, Dartmouth College, Hanover, NH, USA.ORCID http://orcid.org/0000-0001-7835-3621
Jonathan R McDanielDepartment of Chemical Engineering, University of Texas at Austin, Austin, TX, USA.
Emily MakowskiDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.
Peter M TessierDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA.
Aaron S MeyerDepartment of Bioengineering, University of California at Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-4513-1840
Pierre BruhnsUnit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERMF-75015, Paris, France. bruhns@pasteur.fr.
George GeorgiouDepartment of Chemical Engineering, University of Texas at Austin, Austin, TX, USA. gg@che.utexas.edu.

Funding

Understanding the role of RNA-binding protein mutations in cancerP20GM113132 · NIGMS · DARTMOUTH COLLEGE · PI MADDEN, DEAN R · 2016 to 2025
$25.9M
Design of Antibody Fragments Specific For Amyloidogenic AggregatesR01GM104130 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TESSIER, PETER M · 2014 to 2018
$1.3M
NIGMS NIH HHS P20 GM113132NIGMS NIH HHS R01 GM104130
6 · The paper itself

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiers

PMID31767870
PMCPMC6877538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.